arrow
T

Theodore W. Laetsch

children's hospital of philadelphia
H指数:48
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the Prognostic Relevance of Pre-Treatment Epstein–Barr Virus Levels in Non-Endemic Pediatric Nasopharyngeal Carcinoma

评估非流行区儿童鼻咽癌治疗前EB病毒水平与预后的相关性

Cancers
IF4.4
2026-08-290
OA
A High-Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK-Rearranged Non-Small Cell Lung Cancer

一种高灵敏度循环核酸测序检测方法,用于评估携带ALK重排的非小细胞肺癌儿科患者对阿来替尼的治疗反应

2026-07-010
OA
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial

Tra贝替丁和低剂量伊立替康靶向EWS::FLI1在尤因肉瘤中的作用: 1/2期试验

2026-04-160
PRE
Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

放宽接受Tisagenlecleucel治疗的低负担B-ALL儿童/青年患者的医院邻近要求

2025-10-030
OAAI
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors

阿特珠单抗联合化疗治疗复发或难治性实体瘤患儿的可行性

2025-09-010
OAAI
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults
2025-09-018
PRE
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel

儿科患者接受tisagenlecuecel治疗时血液毒性的表征与预测

2025-07-230
OAAI
Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

新型药物在儿童非横纹肌肉瘤软组织肉瘤中的优先级排序及进一步研究的报告:来自儿童肿瘤组的报告

2025-07-060
PRE
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

放射性碘难治性不可切除或转移性甲状腺癌的再分化疗法:国际甲状腺肿瘤研究组声明

2025-04-300
OAAI
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study

Gaze, M.N.; Handkiewicz-Junak, D.; Hladun, R.; Laetsch, T.W.; Sorge, C.; Sparks, R.; Wan, S.; Ceraulo, A.; Kluczewska-Galka, A.; Gámez-Cenzano, C.; 等. [177Lu]Lu-DOTA-TATE在青少年患者中的安全性及剂量学研究,该患者群体具有生长抑素受体阳性的胃肠胰神经内分泌肿瘤,或嗜铬细胞瘤和副神经节瘤:NETTER-P研究II期试验的初步分析。欧洲核医学与分子影像学杂志,2025, 52, 4001–4015. [Google Scholar] [CrossRef]

2025-04-080
OAAI
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
2024-11-110
PRE
Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

B细胞恢复在复发风险和CD19表型中的作用:tisagenlecleucel用于儿童B淋巴细胞急性白血病真实世界应用的多机构回顾性研究

BLOOD
IF23.1
2024-11-050
PRE